MX392514B - Vacuna para estreptococo del grupo a. - Google Patents

Vacuna para estreptococo del grupo a.

Info

Publication number
MX392514B
MX392514B MX2016013277A MX2016013277A MX392514B MX 392514 B MX392514 B MX 392514B MX 2016013277 A MX2016013277 A MX 2016013277A MX 2016013277 A MX2016013277 A MX 2016013277A MX 392514 B MX392514 B MX 392514B
Authority
MX
Mexico
Prior art keywords
group
spycep
fragment
protein
mammal
Prior art date
Application number
MX2016013277A
Other languages
English (en)
Spanish (es)
Other versions
MX2016013277A (es
Inventor
Manisha Pandey
Michael Batzloff
Michael Good
Original Assignee
Univ Griffith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901382A external-priority patent/AU2014901382A0/en
Application filed by Univ Griffith filed Critical Univ Griffith
Publication of MX2016013277A publication Critical patent/MX2016013277A/es
Publication of MX392514B publication Critical patent/MX392514B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22Cysteine endopeptidases (3.4.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2016013277A 2014-04-15 2015-04-15 Vacuna para estreptococo del grupo a. MX392514B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2014901382A AU2014901382A0 (en) 2014-04-15 Group a streptococcal vaccine
AU2014903042A AU2014903042A0 (en) 2014-08-06 Group a streptococcal vaccine
AU2014904453A AU2014904453A0 (en) 2014-11-05 Group a streptococcal vaccine
PCT/AU2015/050174 WO2015157820A1 (en) 2014-04-15 2015-04-15 Group a streptococcus vaccine

Publications (2)

Publication Number Publication Date
MX2016013277A MX2016013277A (es) 2017-01-18
MX392514B true MX392514B (es) 2025-03-24

Family

ID=54323282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013277A MX392514B (es) 2014-04-15 2015-04-15 Vacuna para estreptococo del grupo a.

Country Status (16)

Country Link
US (2) US10301362B2 (OSRAM)
EP (1) EP3131575B1 (OSRAM)
JP (2) JP2017513849A (OSRAM)
KR (2) KR102744193B1 (OSRAM)
CN (1) CN106794236B (OSRAM)
AU (1) AU2015246654B2 (OSRAM)
BR (1) BR112016023915B1 (OSRAM)
CA (1) CA2945052C (OSRAM)
DK (1) DK3131575T3 (OSRAM)
IL (1) IL248266B (OSRAM)
MX (1) MX392514B (OSRAM)
MY (1) MY191217A (OSRAM)
NZ (1) NZ725212A (OSRAM)
SG (1) SG11201608380PA (OSRAM)
WO (1) WO2015157820A1 (OSRAM)
ZA (1) ZA201607355B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392514B (es) 2014-04-15 2025-03-24 Univ Griffith Vacuna para estreptococo del grupo a.
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Fsbm重組蛋白及其用途
JP7410018B2 (ja) * 2017-08-23 2024-01-09 グリフィス ユニバーシティー A群レンサ球菌に対する免疫原性ペプチド
CN110776508B (zh) * 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
KR102437436B1 (ko) * 2019-04-26 2022-08-30 주식회사 엠디헬스케어 스트렙토코커스 파이오제네스 세균 유래 단백질 및 이의 용도
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2006121656A2 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
US8623356B2 (en) 2005-11-29 2014-01-07 The University Of Sydney Demibodies: dimerization-activated therapeutic agents
EP2292648A3 (en) 2006-07-07 2011-06-08 Intercell AG Small Streptococcus pyogenes antigens and their use
US20090010929A1 (en) * 2006-12-04 2009-01-08 Good Michael F Therapeutic Antibodies, Antibody Fragments and Antibody Conjugates
US8482298B2 (en) 2006-12-18 2013-07-09 Schrader Electronics Ltd. Liquid level and composition sensing systems and methods using EMF wave propagation
JP5653215B2 (ja) 2007-09-12 2015-01-14 ノバルティス アーゲー Gas57変異体抗原およびgas57抗体
US20090162369A1 (en) * 2007-12-12 2009-06-25 Katin Helena Threse Nordstrom Synthetic chimeric peptides
AU2009334428B2 (en) 2008-09-17 2014-02-20 Glaxosmithkline Biologicals S.A. Combination gas vaccines and therapeutics
MX392514B (es) 2014-04-15 2025-03-24 Univ Griffith Vacuna para estreptococo del grupo a.
JP7410018B2 (ja) * 2017-08-23 2024-01-09 グリフィス ユニバーシティー A群レンサ球菌に対する免疫原性ペプチド

Also Published As

Publication number Publication date
US10513544B2 (en) 2019-12-24
AU2015246654A1 (en) 2016-11-03
WO2015157820A1 (en) 2015-10-22
KR20160144455A (ko) 2016-12-16
JP2017513849A (ja) 2017-06-01
KR20230039751A (ko) 2023-03-21
AU2015246654B2 (en) 2019-08-08
KR102744193B1 (ko) 2024-12-19
EP3131575A1 (en) 2017-02-22
KR102730367B1 (ko) 2024-11-15
IL248266A0 (en) 2016-11-30
BR112016023915A2 (pt) 2017-10-17
JP2021042247A (ja) 2021-03-18
DK3131575T3 (da) 2024-05-21
IL248266B (en) 2021-09-30
MX2016013277A (es) 2017-01-18
SG11201608380PA (en) 2016-11-29
EP3131575B1 (en) 2024-05-08
CN106794236B (zh) 2021-09-03
CA2945052A1 (en) 2015-10-22
ZA201607355B (en) 2019-03-27
CN106794236A (zh) 2017-05-31
BR112016023915B1 (pt) 2024-03-12
JP7072921B2 (ja) 2022-05-23
NZ725212A (en) 2023-04-28
US10301362B2 (en) 2019-05-28
CA2945052C (en) 2023-05-02
EP3131575A4 (en) 2017-11-01
US20190256562A1 (en) 2019-08-22
US20170037087A1 (en) 2017-02-09
MY191217A (en) 2022-06-09

Similar Documents

Publication Publication Date Title
MX392514B (es) Vacuna para estreptococo del grupo a.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
IL270090B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL255106A0 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
IL263846B (en) Formulation of a peptide vaccine
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
EA201790239A1 (ru) Молекула-носитель для антигенов
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
MX375524B (es) Anticuerpos anti-axl.
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
MY191539A (en) Streptococcal vaccine
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
BR112017023131A2 (pt) anticorpos anti- fcrn
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
MX2017003121A (es) Formulaciones de anticuerpos.
MX2016005956A (es) Anticuerpos especificos para fcrn.
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.
MX380411B (es) Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
DK3523653T3 (da) Rep-protein som protein-antigen til brug i diagnostiske analyser
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer